MARKET

MLYS

MLYS

Mineralys Therapeutics, Inc.
NASDAQ
23.92
+0.30
+1.27%
Pre Market: 24.20 +0.28 +1.17% 04:12 06/16 EDT
OPEN
23.98
PREV CLOSE
23.62
HIGH
24.16
LOW
23.40
VOLUME
82
TURNOVER
0
52 WEEK HIGH
47.65
52 WEEK LOW
12.59
MARKET CAP
2.11B
P/E (TTM)
-11.6331
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MLYS last week (0608-0612)?
Weekly Report · 1d ago
Mineralys Reports Lorundrostat Reduced Heart Failure Risk Biomarkers In Hypertension Trials
NASDAQ · 1d ago
New Heart Failure Biomarkers For Lorundrostat Could Be A Game Changer For Mineralys Therapeutics (MLYS)
Simply Wall St · 1d ago
Reported Sunday, Mineralys Therapeutics Presents Late-Breaking Data At ENDO 2026 Showing Lorundrostat Associated With Significant Reductions In Six Of Eleven Heart Failure Risk Biomarkers
Benzinga · 1d ago
Mineralys posts ENDO 2026 lorundrostat biomarker presentation on uncontrolled hypertension
PUBT · 1d ago
Mineralys Therapeutics presents late-breaking data on lorundrostat
TipRanks · 1d ago
Mineralys says lorundrostat reduces heart failure risk biomarkers in post hoc analysis of hypertension trials
PUBT · 1d ago
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Barchart · 2d ago
More
About MLYS
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.

Webull offers Mineralys Therapeutics Inc stock information, including NASDAQ: MLYS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLYS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MLYS stock methods without spending real money on the virtual paper trading platform.